ReviewNature reviews. Endocrinology2009
Antidiabetic agents and cardiovascular risk in type 2 diabetes.
Review in Nature reviews. Endocrinology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Effect of metformin on adverse outcomes in T2DM patients: Systemic review and meta-analysis of observational studies.Frontiers in cardiovascular medicine · 2022Pooled it
- Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study.Cardiovascular diabetology · 2016Trial
- Plasma metabolomics disentangles T2DM- and CAD-specific dysmetabolism and identifies potential biomarkers for CAD risk escalation in diabetic patients.Cardiovascular diabetology · 2025Article
- Evaluation of Hypoglycemic Polyphenolic Compounds in Blueberry Extract: Functional Effects and Mechanisms.Antioxidants (Basel, Switzerland) · 2024Article
- Rationale, Design, and Baseline Characteristics of the Utopia Trial for Preventing Diabetic Atherosclerosis Using an SGLT2 Inhibitor: A Prospective, Randomized, Open-Label, Parallel-Group Comparative Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2017Article
- Naturally improving insulin resistance with amorfrutins.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- Therapeutic effects of metformin in breast cancer: involvement of the immune system?Cancer immunology, immunotherapy : CII · 2011Article
- Management of diabetes and associated cardiovascular risk factors in seven countries: a comparison of data from national health examination surveys.Bulletin of the World Health Organization · 2011Article
- Direct activation of Epac by sulfonylurea is isoform selective.Chemistry & biology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the clear relationship between HbA(1c) levels and risk of cardiovascular disease in patients with type 2 diabetes mellitus (T2DM) in epidemiologic studies, prospective data on the role of glucose-lowering therapy in reducing cardiovascular events are equivocal. Initial studies of intensive glycemic control suffered from inadequate statistical power to show reductions in cardiovascular events, as well as a lack of durable glycemic control and relatively poor control of associated cardiovascular risk factors. Subsequently, controversy existed over whether rosiglitazone was associated with an increased risk of myocardial ischemic events. Large, prospective, cardiovascular outcome trials that assessed intensive glycemic control versus standard glycemic control have had disappointing results; however, cardiovascular event rates seem to be declining substantially in patients with T2DM managed with aggressive global cardiovascular risk factor modification, which might have masked the benefits of glycemic control. Individuals with T2DM without a history of cardiovascular disease, as well as younger individuals with more modest elevations of HbA(1c), may benefit from a more intensive glucose-lowering strategy. A comprehensive and multifactorial intervention strategy that includes aggressive glycemic control, blood-pressure-lowering and lipid-lowering therapy, aspirin use and lifestyle modifications is beneficial in reducing both macrovascular and microvascular events in patients with T2DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.